alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 117 studies with an author at Weill Cornell Medicine (US) (page 1 of 5) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Microglial activation and tau propagate jointly across Braak stages

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Nature medicine 2021-08-26

Compelling experimental evidence suggests that microglial activation is involved in the spread of tau tangles over the neocortex in Alzheimer's disease (AD). 4 key findings →

Design: longitudinal study Participants: 130 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA neurology 2022-03-01

This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. 3 key findings →

Design: cross-sectional Participants: 97 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA network open 2020-08-03

Black decedents were less likely than White decedents to use hospice for 3 or more days (132 of 378 [34.9%] vs 385 of 834 [46.2%]; P Conclusions and relevance Despite the increase in the use of hospice care in recent decades, racial disparities in the use of hospice remain, especially for noncancer deaths. 1 key finding →

Design: cohort study Participants: 1,212 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer disease and associated disorders 2007-04-01

This study examined the efficacy and safety of memantine monotherapy in patients with moderate-to-severe Alzheimer disease (AD). 5 key findings →

Participants: 350 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Nature communications 2018-10-15

The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct disease trajectories. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effectiveness of a modified Continuum curriculum for medical students: a randomized trial

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2011-01-01

The Continuum: Dementia for Medical Students curriculum provided an inexpensive and readily implementable means for improving medical knowledge of dementia. 2 key findings →

Design: longitudinal study Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Digital Reminiscence for Predeath Grief Among Family Caregivers of Patients With Dementia: A Pilot Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2026-04-01

This pilot randomized clinical trial demonstrated the feasibility, acceptability, and preliminary efficacy of LMH-4-DCP in reducing caregiver grief, with improvements in caregiver-care recipient relationship quality. 5 key findings →

Design: RCT Participants: 68 Evidence: preliminary

Full summary, score breakdown and related studies → Original source Free full text

Education Research: Online Alzheimer education for high school and college students: A randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Neurology 2020-07-14

Online education involving a celebrity may be an effective strategy for educating college students about AD risk reduction strategies. 1 key finding →

Design: randomized controlled trial Participants: 721 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Alzheimer disease and associated disorders 2003-04-01

Advances in genetic research have provided a basis for susceptibility testing for Alzheimer disease (AD). 2 key findings →

Design: randomized controlled trial Participants: 160 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature Medicine 2026-04-15

Biomarkers to determine underlying frontotemporal lobar degeneration (FTLD) tau or TAR DNA-binding protein (TDP) pathology during life are needed to advance clinical trials targeting specific FTD pathologies. 3 key findings →

Participants: 513 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Blood Pressure and Cognitive Decline Over 8 Years in Middle-Aged and Older Black and White Americans

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Hypertension (Dallas, Tex. : 1979) 2019-02-01

Although the association between high blood pressure (BP), particularly in midlife, and late-life dementia is known, less is known about variations by race and sex. 5 key findings →

Design: cohort study Participants: 2,003 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Fluids and barriers of the CNS 2017-05-10

The purpose of this systematic review and meta-analysis was to evaluate the performance of cerebrospinal fluid (CSF) beta amyloid 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) as potential diagnostic biomarkers for idiopathic normal-pressure hydrocephalus (iNPH) and to assess their utility indistinguishing patients with iNPH from those with Alzheimer disease (AD) and healthy normal controls. 4 key findings →

Design: systematic review Participants: 413 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Barriers and Consequences of Prior Authorization for Neurologic Medications

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA Neurology 2025-12-08

A total of 364 studies were identified using our search strategy on Ovid, 278 records were screened, and 20 studies were included in this review. 5 key findings →

Design: meta-analysis Participants: 364 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01

Oral benfotiamine is safe and potentially efficacious in improving cognitive outcomes among persons with MCI and mild AD. 5 key findings →

Design: randomized controlled trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Nature Neuroscience 2025-03-13

Recent studies suggest the existence of brain-first and body-first subtypes within the Lewy body disorder (LBD) spectrum, including Parkinson's disease. 1 key finding →

Participants: 173 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia?

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Neurology Genetics 2026-09-25

Mary Poppins famously asserted that "a spoonful of sugar helps the medicine go down," but this bon mot is likely wrong in almost every way. 1 key finding →

Design: meta-analysis Participants: 74,148 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Emergency Department Hallways Are Associated With Incident Delirium and Severe Agitation in Older Adults Living With Dementia

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of the American Geriatrics Society 2026-01-16

Our sample included 11,105 patients (median age 77, 51% female), with 2299 in the hallway group and 8806 in the non-hallway group. 5 key findings →

Design: retrospective cohort Participants: 11,105 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed